Press release 📈 Stocks 🌍 GLOBAL

Isomorphic Labs Secures $5 Billion Series C to Advance AI Drug Discovery

AI-driven drug discovery firm Isomorphic Labs raised $5 billion in a Series C round led by Greenoaks and Sequoia Capital to accelerate its pipeline and global bioengineering infrastructure.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: GOOGL → 1/10 (50% confidence).

📊 Affected Assets (1)

GOOGL
Neutral 🤖 50%
📅 Short-term 🌍 US ✨ Inferred

Alphabet is the only listed company named: it invested significantly again in Isomorphic Labs' $5 billion Series C. For Alphabet, a large market-cap company, the size of this follow-on stake is not disclosed and is unlikely to move the share price. Isomorphic Labs itself is private, so the headline round is not directly tradable.

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Isomorphic Labs raised $5 billion in a Series C round led by Greenoaks and Sequoia Capital.
  • Alphabet participated in the funding round alongside existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.
  • The capital will support the expansion of the IsoDDE engine and the advancement of internal drug candidates into clinical trials.
  • The company is currently developing therapeutic programs in the fields of oncology and immunology.

📝 Executive Summary

Isomorphic Labs has closed a $5 billion Series C funding round led by Greenoaks and Sequoia Capital. The company plans to use the capital to scale its proprietary AI drug design engine, IsoDDE, and transition its internal oncology and immunology candidates into clinical trials.

❓ FAQ

Can I buy shares in Isomorphic Labs after this funding round?

No. Isomorphic Labs is privately held; the $5 billion Series C was raised from investors such as Greenoaks, Sequoia Capital, Andreessen Horowitz and Alphabet, and there is no public listing mentioned.

How much is Alphabet investing in Isomorphic Labs?

The article only states that Alphabet invested significantly again; no investment amount is given.